Prenatal identification of trisomy 18 (Edwards syndrome)

Abstract

This thesis provides a literature review of trisomy 18 (Edwards syndrome) with a focus on the use of maternal serum and ultrasound markers in the late first and early second trimester of pregnancy to aid in identifying affected pregnancies. Trisomy 18 is, after Down syndrome, the autosomal aneuploidy with the highest birth prevalence, about 2.4/10,000. Only 1 in 5 live born survives to two weeks, with 1 in 20 surviving to one year. Strategies for identifying trisomy 18 in early pregnancy rely on reinterpretation of markers measured as part of Down syndrome screening. Diagnosis requires collecting fetal or placental material obtained from an invasive procedure (amniocentesis or a chorionic villus sampling) and subsequent karyotyping or specific aneuploidy testing such as fluorescent in situ hybridization. The second trimester Triple Test (serum markers alpha-fetoprotein, unconjugated estriol and human chorionic gonadotropin [hCG]) was found to have an 81% detection rate at a 0.4% false positive rate. By adding an additional assay for pregnancy-associated plasma protein-A (PAPP-A), the detection rate improves to 88% while false positives are reduced to 0.1%. In the first trimester, Combined Test, the serum markers (free β hCG and PAPP) in combination with the ultrasound marker nuchal translucency (NT) yields detection and false positive rates of 86% and 0.2%, respectively. For both Tests, hCG and free β hCG measurements are essentially interchangeable. Combining existing markers from both trimesters into a Full Integrated Test (NT, PAPP-A, and the Triple Test), also yields high performance (91% detection rate at 0.2% false positive rate). Ultrasound markers, apart from NT, are not suitable for routine practice, but some could be used in specialist centers. In the future, testing of circulating cell free nucleic acids in maternal plasma may allow for a reduction in the use of invasive procedures.